Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    18936475 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
Condition: Kidney Cancer
Interventions: Biological: bevacizumab;   Biological: recombinant interferon alfa
2 Active, not recruiting Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors
Conditions: Metastatic Renal Cell Carcinoma;   Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed
Intervention: Drug: Association of Bevacizumab (BVC)+ Pazopanib (PZP)

Indicates status has not been verified in more than two years